

Cytotoxic C₃₅ Terpenoid Cryptotrione from the Bark of *Cryptomeria japonica*


Cheng-Chi Chen,[†] Jyh-Horng Wu,[▽] Ning-Sun Yang,[‡] Jang-Yang Chang,^{§,||}
Ching-Chuan Kuo,[§] Sheng-Yang Wang,^{▽,#} and Yueh-Hsiung Kuo^{*,†,‡,±}

Department of Chemistry, National Taiwan University, Taipei, Taiwan 106, R.O.C., Agricultural Biotechnology Research Center, Academia Sinica, Taipei 115, Taiwan, R.O.C., National Institute of Cancer Research, National Health Research Institutes, Taipei 114, Taiwan, R.O.C., Division of Hematology/Oncology, Tri-service General Hospital, National Defense Medical Center, Taipei 114, Taiwan, R.O.C., Tsuzuki Institute for Traditional Medicine, College of Pharmacy, China Medical University, Taichung 404, Taiwan, R.O.C., and Department of Forestry, National Chung-Hsing University, Taichung, Taiwan, R.O.C.

yhkuo@ntu.edu.tw

Received April 19, 2010

ABSTRACT



Cryptotrione (1)

A novel C₃₅-terpene, designated as cryptotrione (1), with an unprecedented skeleton possessing an abietane diterpene with a unique bicyclic sesquiterpene, is identified from the bark of *Cryptomeria japonica*. The carbon skeleton of 1 represents a new structural entity, and this is an intriguing addition to the structurally diverse diterpene-sesquiterpene class. A unique biosynthetic pathway is proposed to support the production of this phytochemical. Notably, 1 exhibits anticancer activity with an IC₅₀ value of 6.44 ± 2.23 μM.

Cryptomeria is a genus of conifer in the cypress family Cupressaceae; it includes only one species, *Cryptomeria japonica* D. DON. It is endemic to Japan, where it is known

as *Sugi* (Japanese cedar),¹ the national tree of Japan. The wood is scented, reddish-pink in color, lightweight but strong, waterproof, and resistant to natural decay. It is favored in Japan for a wide range of construction works as well as for interior paneling and other usage. Because of its industrial importance, the constituents of the leaves and heartwood of *C. japonica* including terpenoids have been actively investigated by many research groups.^{2–20} In regard to biotech-

[†] National Taiwan University.

[‡] Academia Sinica.

[§] National Health Research Institutes.

^{||} National Defense Medical Center.

[±] China Medical University.

[▽] National Chung-Hsiung University.

[#] Equal contribution to this work.

(1) Gan, W. S. *Manual of Medicine Plants in Taiwan*; National Research Institute of Chinese Medicine: Taipei, Taiwan, 1958; Vol. 1, pp 54–55.

(2) Shieh, M.; Iizuka, Y.; Matsubara, Y. *Agric. Biol. Chem.* **1981**, *45*, 1493–1495.


(3) Nagahama, S.; Tazaki, M. *Mokuzai Gakkaishi* **1993**, *39*, 1077–1083.

nological applications, the bark extracts have been found to exhibit antimicrobial activities against some plant pathogenic fungi.²¹ The bark of *C. japonica* has also been employed as a substrate for horticultural crops in soil-less culture, and it has been reported that the replacement of rock wool with processed bark reduces losses caused by soil-borne plant pathogens.^{22,23}

A previous study on the bark of *C. japonica* resulted in the isolation of an abietane-type diterpene quinone, and its antifungal and cytotoxic activities were reported.²⁴ Recently, an investigation of the acetone extract of its bark revealed eight new compounds.^{25,26} It was contemplated that some of the newly reported abietane-type diterpenes might have unique skeleton structures that could incorporate an abietane diterpene and a cadinane sesquiterpene or a 1,10-secocadinane sesquiterpene. Therefore, we conducted a study on the chemical ingredients of the bark of *C. japonica* as an investigation on the bioactive constituents, and we report here a new compound with a unprecedented skeleton that can confer cytotoxic activity.

The bark of *C. japonica* D. Don was collected in Sitou, Taiwan in June, 2000. The air-dried bark (16.0 kg) was extracted with MeOH (3 × 100 L) at room temperature and concentrated to yield a crude extract (520 g), which was then partitioned between H₂O and EtOAc. The EtOAc fraction (430 g) was

subsequently chromatographed repeatedly on silica gel and by HPLC (LDC Analytical-III; Purospher STAR, Merck, 250 mm × 10 mm, EtOAc/hexane 3:17) to give **1**.



1

Crytotrione (**1**)²⁷ was considered to have the molecular formula of C₃₅H₄₈O₄ based on the HREIMS of the molecular ion peak at *m/z* 532.3548 [M]⁺ (calcd 532.3554), suggesting the presence of 12 degrees of unsaturation. The IR spectrum of **1** showed absorption bands at 3310 cm⁻¹, indicating the presence of hydroxyl, and 1699, 1613 cm⁻¹ for the carbonyl groups (including the isolated and conjugated ones) and conjugated double bond. The presence of conjugated carbonyls was also supported by UV absorptions (λ_{max} 335, 348 nm). There were 35 signals observed in the ¹³C NMR spectrum.²⁷ Analysis of the ¹³C NMR, DEPT, and HMQC spectra revealed that **1** contained eight sp³ methyls, eight sp³ methylenes (δ_C 42.0, 41.6, 36.6, 31.3, 26.9, 23.9, 19.5 and 18.6), seven sp³ methines (δ_C 50.7, 46.6, 31.3, 32.0, 29.0, 25.5 and 24.3), 12 quaternary carbons {three sp³ (δ_C 58.3, 38.7 and 33.8), nine sp² including six olefinic carbons (δ_C 152.0, 149.0, 144.8, 144.5, 136.2 and 123.6), and three carbonyls [δ_C 209.0 (C-10', acetyl), δ_C 205.1 (C-15', cyclopentenone), and δ_C 182.5 (C-12, cyclohexadienone chelating with enol)]}. Careful analysis of the ¹H NMR spectrum indicated the presence of three tertiary methyl signals at δ_H 1.17 (s), 0.98 (s), and 0.94 (s), an isopropyl group signal at δ_H 3.00 (sep, *J* = 7.0 Hz, 1H), 1.35 and 1.24 (d, *J* = 7.0 Hz, 3H each), an allylic methylene at δ_H 2.66 (dd, *J* = 15.5, 3.5 Hz, H-6e) and 2.20 (dd, *J* = 15.5, 12.5 Hz, H-6a), a 11-hydroxy-12-oxoabietatriene H_β-1 type signal at δ_H 2.79 (br d, *J* = 12.5 Hz),²⁸ and an intramolecular five-membered ring hydrogen bonding at at δ_H 7.70 (s), together indicating

(27) Crytotrione (**1**): yellow needles, mp 185–187°; [α]_D²⁵ 37.1 (c 0.5, CHCl₃). UV (MeOH) λ_{max} (log ε) nm: 266 (4.21), 335 (4.49), 348 (4.56), 731. EIMS *m/z* (%): 532 (M⁺, 100), 514 (9), 489 (23), 406 (13), 353 (41), 109 (6), 69 (8), 55 (12). HREIMS *m/z* 532.3548 [M]⁺ (calcd for C₃₅H₄₈O₄ 532.3554). ¹H NMR (CDCl₃): δ 0.73 (1H, m, H-7'), 0.85 (3H, d, *J* = 7.0 Hz, H-12'), 0.90 (d, *J* = 7.0 Hz, H-13'), 0.93 (1H, overlap, H-6'), 0.94 (3H, s, H-18), 0.98 (3H, s, H-19), 1.07 (1H, dd, *J* = 6.5, 3.5 Hz, H-5'), 1.17 (3H, s, H-20), 1.23 (1H, overlap, H-3a), 1.24 (3H, d, *J* = 7.0 Hz, H-17), 1.35 (3H, d, *J* = 7.0 Hz, H-16), 1.47 (1H, overlap, H-3b), 1.48 (1H, overlap, H-1'), 1.49 (1H, overlap, H-5), 1.52 (1H, overlap, H-3'), 1.59 (1H, m, H-1a), 1.60 (3H, m, H-8', -2a), 1.67 (1H, overlap, H-2b), 1.71 (1H, overlap, H-11'), 1.76 (3H, m, H-3', -2'), 2.12 (3H, s, H-14'), 2.20 (1H, dd, *J* = 15.5, 12.5 Hz, H-6b), 2.29 (1H, m, H-2'), 2.46 (2H, m, H-9'), 2.66 (1H, dd, *J* = 15.5, 3.5 Hz, H-6a), 2.79 (1H, br d, *J* = 12.5 Hz, H-1b), 3.00 (3H, sep, *J* = 7.0 Hz, H-15). ¹³C NMR (CDCl₃) δ 18.6 (C-2), 19.3 (C-20), 19.5 (C-6), 20.0 (C-13'), 20.4 (C-12'), 20.5 (C-16), 20.8 (C-17), 22.0 (C-19), 23.9 (C-8'), 24.3 (C-1'), 25.5 (C-6'), 29.0 (C-15), 26.9 (C-2'), 29.9 (C-14'), 31.3 (C-11', -3'), 32.0 (C-5'), 33.3 (C-4), 36.6 (C-1), 33.8 (C-18), 38.7 (C-10), 41.6 (C-3), 42.1 (C-9'), 46.6 (C-7'), 50.7 (C-5), 58.3 (C-4), 123.6 (C-9), 136.2 (C-13), 144.5 (C-8), 144.8 (C-11), 149.0 (C-14), 152.0 (C-7), 182.5 (C-12), 205.1 (C-15'), 209.0 (C-10').

(4) Nagahama, S.; Tazaki, M.; Sanetika, T.; Nishimura, K.; Tajima, M. *Mokuzai Gakkaishi* **1996**, *42*, 1121–1126.

(5) Nagahama, S.; Tazaki, M.; Nomura, H.; Nishimura, K.; Tajima, M.; Iwasita, Y. *Mokuzai Gakkaishi* **1996**, *42*, 1127–1133.

(6) Nagahama, S.; Tazaki, M.; Sanetika, T.; Nishimura, K.; Tajima, M. *Mokuzai Gakkaishi* **1998**, *44*, 282–286.

(7) Morita, S.; Yatagai, M.; Fujita, S. *Mokuzai Gakkaishi* **1995**, *41*, 938–944.

(8) Narita, H.; Yatagai, M.; Ohira, T. *J. Essent. Oil Res.* **2006**, *18*, 68–70.

(9) Shimizu, M.; Tsuji, H.; Shogawa, H.; Fukumura, H.; Tanaami, S.; Hayashi, T.; Arisawa, M.; Morita, N. *Chem. Pharm. Bull.* **1988**, *36*, 3967–3973.

(10) Nagahama, S.; Tazaki, M.; Kobayashi, H.; Sumimoto, M. *Phytochemistry* **1993**, *33*, 879–882.

(11) Su, W. C.; Fang, J. M.; Cheng, Y. S. *Phytochemistry* **1993**, *34*, 779–782.

(12) Su, W. C.; Fang, J. M.; Cheng, Y. S. *Phytochemistry* **1994**, *35*, 1279–1284.

(13) Su, W. C.; Fang, J. M.; Cheng, Y. S. *Phytochemistry* **1994**, *37*, 1109–1114.

(14) Su, W. C.; Fang, J. M.; Cheng, Y. S. *Phytochemistry* **1995**, *39*, 603–607.

(15) Su, W. C.; Fang, J. M.; Cheng, Y. S. *Phytochemistry* **1996**, *41*, 255–261.

(16) Su, W. C.; Fang, J. M.; Cheng, Y. S. *Tetrahedron Lett.* **1995**, *36*, 5367–5370.

(17) Chen, X. H.; Kim, C. S.; Kashiwagi, T.; Tebayashi, S. I.; Horiike, M. *Biosci. Biotechnol. Biochem.* **2001**, *65*, 1434–1437.

(18) Morisawa, J.; Kim, C. S.; Kashiwagi, T.; Tebayashi, S. I.; Horiike, M. *Biosci. Biotechnol. Biochem.* **2002**, *66*, 2424–2428.

(19) Arihara, S.; Umeyama, A.; Bando, S.; Imoto, S.; Ono, M.; Tani, M.; Yoshikawa, K. *Chem. Pharm. Bull.* **2004**, *52*, 354–358.

(20) Shibuya, T. *Phytochemistry* **1992**, *31*, 4289–4294.

(21) Kofujita, H.; Fujino, Y.; Sasaki, T.; Hasebe, M.; Ota, M.; Suzuki, K. *Mokuzai Gakkaishi* **2001**, *47*, 479–486.

(22) Yu, J. Q.; Komada, H. *Plant Epidemic Prevent.* **1995**, *49*, 388–390.

(23) Yu, J. Q.; Komada, H.; Yamamoto, M.; Terada, T.; Matsui, Y. *J. Hortic. Sci.* **1997**, *72*, 989–996.

(24) Kofujita, H.; Ota, M.; Takahashi, K.; Kawai, Y.; Hayashi, Y. *Phytochemistry* **2002**, *61*, 895–898.

(25) Yoshikawa, K.; Suzuki, K.; Umeyama, A.; Arihara, S. *Chem. Pharm. Bull.* **2006**, *54*, 574–578.

(26) Yoshikawa, K.; Tanaka, T.; Umeyama, A.; Arihara, S. *Chem. Pharm. Bull.* **2006**, *54*, 315–319.

that **1** possessed a 11-hydroxy-12-oxoabietatriene type moiety. The gross structure of **1** was deduced from extensive analyses of the 2D NMR data, including the ^1H – ^1H COSY, HMQC, and HMBC spectra in CDCl_3 (Figure 1). The ^1H – ^1H COSY spectrum revealed coupling spin systems of the sequences of H-1 to H-3 and H-5 to H-6. Long range HMBC correlations from CH_3 -19 to C-3, C-5, and C-18; CH_3 -20 to C-1, C-5, and C-9; CH_2 -6 to C-8, and C-10; 11-OH to C-9, C-11, and C-12; and H-15 to C-12, and C-14, constructed the ABC rings of the abietane skeleton.




Figure 1. Key HMBC correlations of compound **1**.

These NMR spectral data resembled those of 11-hydroxy-12-oxoabietatriene-7,9(11),13-triene (**2**) except for the absence of two olefinic signals (H-7 and H-14) of **1**.²⁸ It is suggested that H-7 and H-14 in **2** were substituted as in the case of **1**. Two sets of signals [δ_{H} 2.12 (s), δ_{C} 209.0 and 29.9; δ_{H} 0.90, 0.85 (3H each, d, $J = 7.0$ Hz), having COSY correlation to δ_{H} 1.71 (1H, m, H-11')] indicated the presence of an acetyl and an isopropyl groups. The consecutive protons H-6' (δ_{H} 0.93, m) \rightarrow H-7' (δ_{H} 0.73) \rightarrow H-11' \rightarrow H-12' (H-13'); H-7' \rightarrow H-8' \rightarrow H-9' revealed from the COSY correlation together with the correlations H-14'/C-9', -10'; H-8'/C-9', -10' suggested that the side chain is a 1-isopropyl-4-pentanone. HMBC and COSY cross-peaks indicated the connectivities of H-3' to C-1'-C-5'; H-6' to C-1', C-5', C-7', C-8'; and H-7' to C-6', H-11', H-8', H-9'. The result disclosed the presence of a moiety of bicyclo[3,1,0]hexane, and the side chain linked on C-6' of cyclopropane. Three methine protons presented higher field at δ_{H} 1.07 (H-5'), 0.93 (H-6') and 0.73 (H-7'), and this is an additional proof of the existence of cyclopropane. The HMBC correlations from CH_2 -6 to C-15' showed that C-15' must be connected to C-7. HMBC correlations, H-1', H₂-2', H₂-3', H-5'/C-4' (δ_{C} 58.3); H₂-3'/C-14, C-15' revealed that C-4' is a spiro carbon which bonded four carbons, C-3', C-5', C-14 and C-15'. On the basis of the above evidence, the gross structure of **1** was elucidated as the structure shown in Figure 1.

For the stereochemistry of **1**, NOESY cross-peaks between CH_3 -19, CH_3 -20 and H β -6 showed that **1** has identical relative configuration of trans-fused AB rings to those of common diterpenes reported from *C. japonica*. NOESY correlations of H-15/H-6' and H-1'/H-5', H-7' established the relative configurations at C-1', C-5', and C-6'. X-ray crystallographic





Figure 2. ORTEP drawing of **1**.

Scheme 1. Plausible Biosynthetic Pathway for **1**



analysis (Figure 2), gave the relative configuration of **1**.³⁰ Su et al. has published many new abietane type derivatives from the same plant and elucidated their absolute configuration as 5*S* and 10*S*.^{11–16} The compounds from the same plant would give the same absolute configuration. Consequently, the structure and absolute configuration of **1** was unambiguously established.

A plausible biosynthetic pathway for cryptotrione (**1**) was proposed as shown in Scheme 1. Cryptotrione (**1**) might be derived from a combination of **2** and **3** to form intermediate cation **4** by acid catalytic bond formation, which was

(28) Dellar, J. E.; Cole, M. D.; Waterman, P. G. *Phytochemistry* **1996**, *41*, 735–738.

(29) Finlay, G. J.; Baguley, B. C.; Wilson, W. R. *Anal. Biochem.* **1984**, *139*, 272–277.

(30) X-ray data have been included in Supporting Information.

followed via cyclization and rearrangement to yield **5**. After dehydrogenation, oxidation at C-15' and oxidative cleavage of C1'-C10' bond of the sesquiterpene moiety produced trione **6**. Finally, **6** was cyclized by acidic catalysis to generate the compound **1**.

Cryptotrione (**1**) was evaluated for potential antitumoral cytotoxicity against human oral epidermoid carcinoma KB cells. After treating KB cells with various concentrations of test compounds for population doubling times (each time about 72 h), the cell viability was assessed using a methylene blue dye assay.²⁹ The result demonstrated that **1** exhibited an IC₅₀ value of $6.44 \pm 2.23 \mu\text{M}$. This compound thus possesses a medium cytotoxic property that is slightly weaker

than that of the clinically used anticancer drug, etoposide (VP-16, IC₅₀ value $2.0 \mu\text{M}$).

Acknowledgment. The authors thank China Medical University (CMU96-104), Taiwan Department of Health Clinical Trial Research Center of Excellence (DOH99-TD-B-111-004) and of Health Cancer Research Center of Excellence for financial support (DOH99-TD-C-111-005).

Supporting Information Available: ¹H and ¹³C NMR, 2D spectra, and X-ray data of cryptotrione (**1**) and experimental procedures. This material is available free of charge via the Internet at <http://pubs.acs.org>.

OL1009027